Financial Report
The following transactions have been entered into with related parties:
|
2021 kEUR |
Income from related parties |
Purchases from related parties |
Amounts due from related parties |
Amounts due to related parties |
|
|
|
|
|
|
|
Entity with control over the company |
|
|
|
|
|
Draupnir Holding B.V. |
6,794 |
-221 |
– |
– |
|
|
|
|
|
|
|
Other related entities |
|
|
|
|
|
Thalamus |
– |
-167 |
– |
-404 |
|
Ferring Group |
36,169 |
-3 |
2,999 |
– |
|
Monedula AB |
355 |
-1,224 |
438 |
-11,447 |
|
Amzell B.V. |
166 |
– |
– |
– |
|
Amring Pharmaceuticals Inc |
9 |
– |
– |
– |
|
Basell Pharma AG |
1 |
– |
– |
– |
|
SVAR Life Science AB |
79 |
– |
– |
– |
|
Nordic Pharma Ltd. |
– |
-9 |
– |
– |
|
|
|
|
|
|
|
2020 kEUR |
Income from related parties |
Purchases from related parties |
Amounts due from related parties |
Amounts due to related parties |
|
|
|
|
|
|
|
Other related entities |
|
|
|
|
|
Draupnir Holding B.V. |
– |
-649 |
21 |
– |
|
Thalamus |
– |
-247 |
– |
-542 |
|
Ferring Group |
39,217 |
– |
2,372 |
– |
|
Monedula AB |
703 |
-1,144 |
189 |
-12,169 |
|
Amzell B.V. |
266 |
– |
33 |
– |
|
Blekebo |
– |
-30 |
– |
– |
All disclosed related parties are either related through the Esperante Investments S.à r.l. ownership structure or through managerial control. Esperante Investments S.à r.l. is a higher parent company of our majority shareholder Draupnir Holding B.V.
Income from Draupnir Holding B.V. primarily relates to reimbursement of IPO recognition bonuses.
Purchases from and amounts due from Draupnir Holding B.V. relate to service and insurance fees.
Purchases from and amounts due to Thalamus AB relate to rental of premises.
Income from the Ferring Group and amounts due from the Ferring Group relate to sale of goods.
Purchases from Monedula AB relates to the lease of premises. Income from Monedula relates to property management fees and recharged improvements to the premises. Amounts due to Monedula AB relate to the financial liability as disclosed in Note 19.
During the year, no provisions for doubtful debt and no write-offs on receivables from related parties were recognized (2020: nil). No guarantees were given or received for any outstanding related party balances (2020: nil).
Compensation of key management personnel of the Group:
|
kEUR |
2021 |
2020 |
|
|
|
|
|
Salaries and short-term benefits |
3,454 |
2,089 |
|
Post-employment benefits |
279 |
113 |
|
Share-based payment expense |
4,206 |
0 |
|
Total transactions with key management |
7,939 |
2,202 |
Reference is made to Note 4 for further details on the share-based payment expense.
Key management personnel are considered all members of the Executive Committee and the Board of Directors. Due to the IPO in April 2021 the composition of the key management personnel was changed. As a result, the amounts for 2021 and 2020 are not readily comparable.